Article

Comprehensive care beneficial in managing RCC events

About half of physicians treating patients with advanced renal cell carcinoma (RCC) believe that working with a comprehensive care team is extremely beneficial in helping to effectively manage adverse events associated with newer targeted therapies, according to a recently released survey.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke
The phase 1 study is set to begin later this year.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
FDA approves label expansion for Rezūm Water Vapor Thermal Therapy for BPH
June 20th 2025

FDA approves label expansion for Rezūm Water Vapor Thermal Therapy for BPH

Hannah Clarke
The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates,
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Katie S. Murray, DO, MS
June 18th 2025

Clinical Forum: Advances in low-grade UTUC treatment and care

Urology Times staff
The conversation touched on risk stratification, which plays a central role in deciding among surgical options.
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
June 18th 2025

Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC

Hannah Clarke
The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
© 2025 MJH Life Sciences

All rights reserved.